• Leadership Profiles

    Edward J. Benz Jr., MD
    President and Chief Executive Officer

    Edward J. Benz Jr., MD

    Edward J. Benz Jr., MD, became the president and chief executive officer of the Institute in 2000 and also serves as chief executive officer of Dana-Farber/Partners CancerCare, director of Dana-Farber/Harvard Cancer Center, and a trustee of Dana-Farber/Children's Hospital Cancer Care. Dr. Benz is presently the Richard and Susan Smith Professor of Medicine, professor of Pediatrics, professor of Pathology, and faculty dean for Oncology at Harvard Medical School.

    He received a bachelor's degree, cum laude, from Princeton University, a medical degree, magna cum laude, from Harvard Medical School, and a master's degree (privatum) from Yale University.

    Immediately prior to assuming the presidency of the Institute, Dr. Benz was chairman of the Department of Medicine at the Johns Hopkins University School of Medicine and the Sir William Osler Professor of Medicine.

    Author of more than 200 articles, books, chapters, reviews, and abstracts, Dr. Benz is a past president of both the American Society of Hematology and the American Society of Clinical Investigation, and is currently an associate editor of the New England Journal of Medicine.

    Make a gift in honor of Dr. Benz as he retires from his role as President and CEO of Dana-Farber and continue his legacy investing in the work of our extraordinary scientists and compassionate care for our patients.

    Dorothy E. Puhy
    Executive Vice President and Chief Operating Officer

    Dorothy Puhy

    Dorothy E. Puhy became the Institute's chief operating officer in 2012. She previously served as chief financial officer and director for Fiscal Services since 1994, and executive vice president since 2004. Ms. Puhy is chief administrative officer of Dana-Farber/Partners CancerCare and treasurer of HealthCare Dimensions, Inc.

    Prior to joining Dana-Farber, she was chief financial officer at New England Medical Center in Boston and a senior manager at Ernst and Whinney. Ms. Puhy received her bachelor's degree from the University of Pennsylvania and her business degree from its Wharton School.

    Richard S. Boskey
    Senior Vice President and General Counsel

    Richard Boskey

    Richard S. Boskey joined the Institute in 1999. He serves as assistant secretary of Dana-Farber Cancer Institute and Dana-Farber/Partners CancerCare, and secretary of the Dana-Farber Trust, Inc. and Dana-Farber/Children's Hospital Cancer Care. Previously, he served in various positions at Partners HealthCare and Massachusetts General Hospital, including deputy general counsel, and was an associate at the law firm Hill & Barlow. Mr. Boskey received his bachelor's degree from Brown University and his master's and law degrees from the University of Virginia.

    Craig A. Bunnell, MD, MPH, MBA
    Chief Medical Officer

    Craig Bunnell

    Craig A. Bunnell, MD, MPH, MBA, became the chief medical officer and medical director for Adult Ambulatory Oncology in 2012. Dr. Bunnell received his bachelor's degree, summa cum laude, from Colorado College after which he was a Thomas J. Watson Fellow in Stockholm, Sweden. He earned his medical degree from Harvard Medical School and his MPH from the Harvard School of Public Health. He also earned his MBA from the Sloan School of Management at the Massachusetts Institute of Technology. Dr. Bunnell completed his internship, residency and fellowship in hematology and oncology at Brigham and Women's Hospital, where he also served as chief medical resident. Dr. Bunnell is a medical oncologist involved in research and the care of patients with breast cancer in the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute.

    James D. Griffin, MD
    Chair, Department of Medical Oncology

    James Griffin.jpg

    James D. Griffin, MD, received his medical degree from Harvard Medical School in 1974. After residency training in internal medicine at Johns Hopkins Hospital, he completed a hematology fellowship at Massachusetts General Hospital and a medical oncology fellowship at Dana-Farber. In 1981, he joined the staff of Dana-Farber, where he currently is director of the Leukemia Program and chair of the Department of Medical Oncology.

    From 1993 to 1998, Dr. Griffin was editor-in-chief of Blood. He is a professor of Medicine at Harvard Medical School and currently sits on the scientific advisory boards of the Lombardi Cancer Center at Georgetown University and the Johns Hopkins Cancer Center and Case Western Cancer Center.

    Daphne Haas-Kogan, MD
    Professor and Chair, Department of Radiation Oncology
    Dana-Farber Cancer Institute/Brigham and Women’s Hospital/Boston Children’s Hospital

    Daphne Haas-Kogan, MD

    Daphne Haas-Kogan, MD, received her medical degree from the University of California at San Francisco (UCSF) in 1991. She completed a research fellowship, followed by residency in radiation oncology at the UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC). Dr. Haas-Kogan spent 18 years as a radiation oncologist, researcher, and academic leader in the UCSF HDFCCC system before becoming chair of the Department of Radiation Oncology at Dana-Farber, Brigham and Women’s Hospital, and Boston Children’s Hospital in 2015.

    William C. Hahn, MD, PhD
    Chair, Executive Committee for Research (ECR)

    William Hahn, MD, PhD

    William C. Hahn, MD, PhD, is chair of the Executive Committee for Research at Dana-Farber, where he has been engaged in clinical care and research since 1996. He is chief of the Division of Molecular and Cellular Oncology in the Department of Medical Oncology and an Institute Member of the Broad Institute of MIT and Harvard. He received his AB in Biochemical Science, PhD in Immunology and MD all from Harvard University and completed his clinical training at Massachusetts General Hospital and Dana-Farber Cancer Institute. His research focuses on understanding how mutations cooperate in cancer initiation and progression to develop rational combination therapies.

    Deborah Hicks
    Senior Vice President for Human Resources

    Deborah Hicks

    Deborah Hicks joined Dana-Farber as the senior vice president for Human Resources in 2011. Prior to joining Dana-Farber, Ms. Hicks served as the associate dean and chief human resources officer at Harvard Medical School.

    She joined Harvard Medical School in January 2009. Previously, Ms. Hicks was the vice president of Human Resources at Harvard Pilgrim Health Care (HPHC), joining HPHC in 1988 and becoming vice president of Human Resources and part of the leadership team in 1999, where she was instrumental in supporting the organization during the turnaround of HPHC from receivership to profitability.

    She currently serves as chair of the Board of the New England Human Resources Association, holds a master's degree in Counseling Psychology/Organizational Management from Antioch University, and a bachelor's degree from the University of Massachusetts at Amherst.

    Joseph Jacobson, MD
    Chief Quality Officer

    Joseph Jacobson, MD

    Joseph Jacobson, MD, joined Dana-Farber Cancer Institute in 2011 as the Institute's first chief quality officer, overseeing clinical quality programs across Dana-Farber and its affiliates, and representing Dana-Farber in regional and national quality improvement efforts. He focuses on clinical process measurement and improvement, efficiency and effectiveness of care, and quality leadership development. He is also a member of and practicing physician in our Thoracic Oncology Program.

    Before joining Dana-Farber, Dr. Jacobson served as the chairman of medicine at North Shore Medical Center. As part of the Partners Healthcare system, he co-developed and currently co-directs the Partners Clinical Process Improvement Leadership Program. He has an extensive track record in quality measurement and quality improvement, serving as a founding member of the American Society of Clinical Oncology (ASCO) Quality Oncology Practice Initiative, as co-developer of the ASCO/ONS Chemotherapy Safety Standards and as recent past Chair of the ASCO Quality of Care Committee.

    Bruce E. Johnson, MD
    Chief Clinical Research Officer

    Bruce E. Johnson, MD

    Bruce E. Johnson, MD, became Dana-Farber’s chief clinical research officer in 2013. He previously was director of the Lowe Center for Thoracic Oncology at Dana-Farber/Brigham and Women’s Cancer Center. He is also professor of Medicine at Harvard Medical School and an American Society of Clinical Oncology translational research professor.

    Johnson graduated from Harvard University and the University of Minnesota Medical School. His postdoctoral training was at the University of Chicago Hospitals and Clinics and the National Cancer Institute. In 1992, he became head of the Lung Cancer Biology Section, Medicine Branch, at the NCI, until 1998, when he joined Dana-Farber.

    Johnson directs the Lung Cancer Program within the Dana-Farber/Harvard Cancer Center. His translational research is devoted to testing novel therapeutic agents for their efficacy against lung cancer and other thoracic malignancies with specific genomic changes.

    Jason M. Johnson, PhD
    Chief Health Information Officer

    Jason M. Johnson, PhD

    Jason M. Johnson, PhD, joined the Institute in April 2016 and serves as Chief Health Information Officer. Prior to joining Dana-Farber, Dr. Johnson was executive vice president and head of R&D at PatientsLikeMe, a patient-focused research company in Cambridge, MA. He came to that position after serving in various leadership roles in scientific informatics, bioinformatics, and genomics at Merck for many years. Dr. Johnson holds AB and BS degrees from Stanford University, a master’s degree from the University of Cambridge (UK), and a PhD in Biophysics from Harvard University.

    Elizabeth A. Liebow
    Senior Vice President of Business Development, Clinical Planning, and Community Site Operations

    Elizabeth A. Liebow

    Elizabeth A. Liebow, who joined Dana-Farber in 2004, is responsible for planning and business development for clinical services at Dana-Farber, as well as operational oversight of Dana-Farber's satellite locations and physician practices. Most notably, she directed the development of Dana-Farber's four satellite clinics and acquisition of eight physician practice sites, facilitated clinical operations planning for the Yawkey Center for Cancer Care, and oversaw strategic clinical growth planning efforts.

    Ms. Liebow is currently focused on developing new partnerships with additional community sites and integrated delivery systems, continuing clinical growth on Dana-Farber's main campus, expanding care beyond New England, and improving efficiency and cost effectiveness in the community-based sites.

    Ms. Liebow holds a Master of Science in Health Policy and Management from the Harvard School of Public Health and a BA in Economics from Brandeis University.

    Maria Megdal
    Senior Vice President for Institute Operations

    Maria Megdal

    Maria Megdal joined Dana-Farber Cancer Institute as the vice president for facilities management and real estate in 2008 and was named senior vice president for institute operations in 2012.

    Before joining Dana-Farber, Ms. Megdal served as vice president for corporate real estate services at Saint Vincent Catholic Medical Centers of New York. Prior to Saint Vincent's, Ms. Megdal held various management roles at Memorial Sloan-Kettering Cancer Center after completing her administrative residency there.

    Ms. Megdal holds a masters in health administration from Cornell University and a bachelors degree in physical anthropology from Rutgers University. She is a longtime member of several alumni boards at Cornell where she serves as adjunct lecturer on facilities planning.

    Drew Memmott
    Senior Vice President for Research, Dana-Farber Cancer Institute
    Associate Director for Administration, Dana-Farber/Harvard Cancer Center

    Drew Memmott

    Drew Memmott joined Dana-Farber in 2014 as the senior vice president for research administration and the associate director for administration for the Dana-Farber/Harvard Cancer Center. Prior to joining Dana-Farber, Mr. Memmott served as the associate director for administration for the Mayo Clinic Cancer Center and as a director for research administration at Columbia University Medical Center. Mr. Memmott received his bachelor's degree from the University of Utah and graduate degrees from the University of Washington and Columbia University.

    Lee M. Nadler, MD
    Senior Vice President, Experimental Medicine

    Lee Nadler.jpg

    Lee M. Nadler, MD, received his medical degree from Harvard Medical School in 1973. After residency training at Columbia-Presbyterian Medical Center, and training at the National Cancer Institute in tumor immunology, he completed a medical oncology fellowship at Dana-Farber, where he joined the staff in 1980. During his tenure at Dana-Farber, he has served as chief of the Division of Hematologic Malignancies and was the first chair of the Department of Adult Oncology. Dr. Nadler is the Virginia and D.K. Ludwig Professor of Medicine at Harvard Medical School and the Pan Mass Challenge Senior Investigator at Dana-Farber.

    Stuart H. Orkin, MD
    Chairman, Department of Pediatric Oncology

    Stuart Orkin

    Stuart H. Orkin, MD, received his medical degree in 1972 from Harvard Medical School, followed by postdoctoral research at the National Institutes of Health and clinical training in pediatrics and hematology-oncology at Children's Hospital Boston and Dana-Farber, where he joined the faculty in 1978. Dr. Orkin is a Howard Hughes Medical Institute Investigator and the David G. Nathan Professor of Pediatrics at Harvard Medical School. Over the past decade, his laboratory has defined critical nuclear regulators of hematopoiesis.

    Susan S. Paresky
    Senior Vice President for Development and the Jimmy Fund

    Susan Paresky.jpg

    Susan S. Paresky joined the Institute in 1997. Prior to this, she was associate dean for Development at the Harvard School of Public Health, where she executed the school's fundraising program as part of Harvard University's $2 billion campaign. She has also held senior positions at Brandeis University and Wheaton College. Ms. Paresky received her business degree from Simmons School of Management and her bachelor's degree from Wheaton College, where she served as a trustee for many years and received an honorary degree in 2011.

    Patricia Reid Ponte, RN, DNSc, FAAN
    Senior Vice President for Patient Care Services and Chief Nursing Officer

    Patricia Reid Ponte

    Patricia Reid Ponte, RN, DNSc, FAAN, also serves as the nursing director of the Hematology/Oncology, Bone Marrow Transplant Program at Brigham and Women's Hospital and as the cancer center nurse leader for Dana-Farber/Partners CancerCare. She received her bachelor's degree in nursing from the University of Massachusetts, Amherst, and her master's and doctorate degrees from Boston University. Dr Reid Ponte completed a three year Robert Wood Johnson Nurse Executive Fellowship in 2004 and was inducted into the American Academy of Nursing.

    Michael L. Reney
    Senior Vice President for Finance and Chief Financial Officer


    Michael Reney joined Dana-Farber in 2015. He previously served as chief financial officer at Brigham and Women’s Hospital (BWH). Mr. Reney began his career as a senior auditor at Deloitte & Touche LLP, after which he joined BWH. His extensive experience includes serving as assistant controller at Massachusetts General Hospital, followed by several positions within Partners Healthcare. In 2000, he returned to BWH as controller and executive director of Finance, and was named senior vice president for finance and chief financial officer for Brigham and Women's Health Care (BWHC) in 2008.

    Mr. Reney holds a bachelor’s degree in accounting from Bentley College and an MBA from the University of Massachusetts, Boston. He is a member of the Healthcare Financial Management Association, as well as the Healthcare Roundtable for CFOs. Mr. Reney serves on the boards of the Fenway Community Health Center, Medical Academic and Scientific Community Organization (MASCO), Brigham Research Foundation, and Longwood Medical Energy Corporation.

    Barrett J. Rollins, MD, PhD
    Chief Scientific Officer

    Barrett  Rollins

    Barrett J. Rollins, MD, PhD, received his doctoral degree in 1979 and medical degree in 1980 from Case Western Reserve University and completed his internship and residency in internal medicine at Beth Israel Hospital, Boston. He then performed clinical and research fellowships in medical oncology at Dana-Farber and joined the Institute's faculty in 1986. Dr. Rollins is currently Professor of Medicine at Harvard Medical School.

    Stephen E. Sallan, MD
    Chief of Staff Emeritus

    Stephen Sallan

    Stephen E. Sallan, MD, joined the institute in 1973 as a trainee before becoming a member of the staff in the Department of Pediatric Oncology. He was named chief of staff and chairman of the Medical Staff Executive Committee in 1995, and chief of staff emeritus in 2012. Dr. Sallan received his undergraduate and medical degrees from Wayne State University. He is presently a professor of Pediatrics at Harvard Medical School, and was named the Quick Family Senior Investigator in 2002.

    Steven R. Singer
    Senior Vice President for Communications

    Steve Singer

    Steven R. Singer joined the Institute in 1997. He previously served as director of Communications and Public Affairs and adjunct lecturer at Harvard University's John F. Kennedy School of Government. He has worked as a press secretary in the U.S. House of Representatives, and is past chair of the National Cancer Institute's Public Affairs Network. Mr. Singer received his bachelor's degree from Colby College and a master's degree in public administration from Harvard University's Kennedy School.

    Robert J. Soiffer, MD
    Chair, Executive Committee for Clinical Programs (ECCP)

    Robert J. Soiffer, MD

    Robert J. Soiffer, MD, is professor of Medicine at Harvard Medical School and institute physician at Dana-Farber. He is chief of the Division of Hematologic Malignancies, vice-chairman of Medical Oncology, and co-director of the Bone Marrow Transplant Service at Dana-Farber. He serves on the Executive Committee for Clinical Practice, the Executive Committee for Clinical Research, and the Executive Patient Safety Oversight Group at Dana-Farber.

    Dr. Soiffer is a former president of the American Society for Blood and Marrow Transplantation. He served on the advisory board for the Center for International Blood and Marrow Transplant Research. He is a member of the executive steering committees for the Blood and Marrow Transplant Clinical Trials Network; serves on the board of directors for the National Marrow Donor Program Be the Match Registry; and serves on the board of the Massachusetts chapter of the Leukemia & Lymphoma Society.

    Richard Stone, MD
    Chief of Staff
    Professor of Medicine, Harvard Medical School

    Richard Stone, MD

    Richard Stone, MD, is director of Dana-Farber's Adult Acute Leukemia Program. Dr. Stone is nationally recognized for his translational and clinical research concerning blood and bone marrow malignancies, including acute leukemia, myeloproliferative disorders, and myelodysplastic syndrome (MDS), a bone marrow failure state that may convert to leukemia.

    In addition to his work at Dana-Farber, Dr. Stone serves as chair of the Medical Oncology Board of the American Board of Internal Medicine, chair of the Medical Advisory Board of the Aplastic Anemia & MDS International Foundation, and chairman of the Leukemia Core Committee for the Alliance for clinical Trials in Oncology.

    Dr. Stone earned his medical degree from Harvard Medical School in 1981. He completed his internal medicine residency training at Brigham and Women's Hospital and his hematology-oncology fellowship at Dana-Farber.

    Scott J. Swanson, MD
    Chief Surgical Officer

    Scott Swanson, MD

    Scott J. Swanson, MD, joined Dana-Farber as chief surgical officer in 2008. He is the Disease Center leader of the Thoracic Oncology Program, and leads a multidisciplinary group focused on optimizing the experience and outcome for patients with thoracic malignancy. Dr. Swanson is also director of the Minimally Invasive Thoracic Surgery Program at Brigham and Women’s Hospital, and professor of Surgery at Harvard Medical School. He received a bachelor’s degree, magna cum laude, from Amherst College, and a medical degree from Harvard Medical School.

    Mary-Ellen Taplin, MD
    Chair, Executive Committee for Clinical Research (ECCR)

    Mary-Ellen Taplin, MD

    Mary-Ellen Taplin, MD, joined the Institute in 2003. She serves as director of clinical research for the Lank Center for Genitourinary Oncology at Dana-Farber /Brigham and Women’s Cancer Center. She is also associate professor of Medicine at Harvard Medical School. She is an investigator on many projects, including the Prostate Cancer Clinical Trial Consortium, Dana-Farber SPORE grant, Stand Up 2 Cancer, and several Prostate Cancer Foundation Challenge Grants. Dr. Taplin has been dedicated to clinical and translational investigations that focus on novel approaches to treating localized high risk prostate cancer and secondary hormone therapy for metastatic castration-resistant prostate cancer. She has described molecular and physiologic alterations in the androgen receptor pathway in the context of prostate cancer resistance. Dr. Taplin is dedicated to patient care and clinical investigation in genitourinary oncology.

    James Tulsky, MD
    Chair, Department of Psychosocial Oncology and Palliative Care

    James Tulsky, MD

    James Tulsky, MD, received his AB from Cornell University, his MD from the University of Illinois College of Medicine at Chicago, and completed internal medicine training at the University of California, San Francisco (UCSF). He continued at UCSF as chief medical resident and subsequently as a Robert Wood Johnson Clinical Scholar. Dr. Tulsky was on the faculty of Duke University from 1993-2015, lastly as professor of Medicine and Nursing and chief, Duke Palliative Care. He joined Dana-Farber Cancer Institute in 2015 to be Chair, Department of Psychosocial Oncology and Palliative Care. Dr. Tulsky has a longstanding research interest in clinician-patient communication and quality of life in serious illness.

    Annick D. Van den Abbeele, MD
    Chief, Department of Imaging

    Annick Van Den Abbeele, MD

    Annick Van den Abbeele, MD, received her BA and MD from the Université Catholique de Louvain in Belgium. Following a residency in Pediatrics at the Université Catholique de Louvain and a Neonatology fellowship at Vanderbilt University Medical Center in Nashville, TN, she completed a residency in Nuclear Medicine and a fellowship in Radiology at Brigham and Women's Hospital, Boston, MA and Harvard Medical School, followed by seven years in basic sciences research. In 1994, Dr. Van den Abbeele assumed the position of Director of Nuclear Medicine at the Dana-Farber Cancer Institute, and in 2004 became the clinical director of Radiology. In 2006, she was promoted to chief of the Department of Imaging. She has been a faculty member at Harvard Medical School since 1987.

    Eric P. Winer, MD
    Chief Clinical Strategy Officer

    Eric P. Winer, MD

    Eric P. Winer, MD, is chief clinical strategy officer. He is chief of the Division of Women's Cancers and director of the Breast Oncology Center at Dana-Farber/Brigham and Women's Cancer Center, and one of the leaders of the Institute's Susan F. Smith Center for Women's Cancers. In addition, he is director of the Dana-Farber/Harvard Cancer Center (DF/HCC) SPORE in Breast Cancer and Professor of Medicine at Harvard Medical School.

    Dr. Winer's BA and MD degrees are from Yale University. He was a physician and associate professor of medicine at Duke University School of Medicine before coming to Dana-Farber in 1997.

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms
  • Contact Us

  • Fast Fact

    • In 1983, the Sidney Farber Cancer Institute was renamed Dana-Farber Cancer Institute in recognition of generous support from the Charles A. Dana Foundation.